Shares of GRAIL, Inc. (GRAL) are surging 5.03% in Tuesday's pre-market trading session, as investors eagerly anticipate the company's first-quarter earnings report scheduled for release after the market close. The biotechnology company, known for its innovative cancer detection technologies, has captured the attention of Wall Street ahead of its financial disclosure.

According to FactSet Research Systems Inc., analysts expect GRAIL to report a loss of $3.99 per share for the quarter. Despite the projected loss, the significant pre-market rally suggests that investors may be optimistic about other aspects of the company's performance or future outlook. Factors such as revenue growth, progress in clinical trials, or potential partnerships could be driving the positive sentiment.

The market's reaction indicates that investors are looking beyond the expected quarterly loss, possibly focusing on GRAIL's long-term potential in the rapidly evolving field of early cancer detection. As the company prepares to unveil its financial results, all eyes will be on key metrics such as cash burn rate, research and development progress, and any forward-looking statements that could provide insight into GRAIL's future prospects.